An Open-Label, Multi-Center Phase I/IIa Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphomas.
Phase of Trial: Phase I/II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Tasidotin (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 20 Jan 2018 Status changed from recruiting to discontinued.
- 26 May 2012 Additional trial locations added as reported by European Clinical Trials Database.
- 18 Jul 2011 New trial record